Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SPRTN is a specialized, DNA-dependent metalloprotease critical for maintaining genome integrity by cleaving DNA-protein crosslinks (DPCs) that would otherwise hinder DNA replication[1][2]. SPRTN activity is tightly regulated: it is recruited to stalled replication forks via PCNA-interacting and ubiquitin-binding domains, is activated by specific DNA structures, and is controlled by posttranslational modifications such as ubiquitination to prevent inappropriate proteolysis[1][2][4]. Its proteolytic activity is restricted to DNA-bound substrates during S phase, thereby resolving cytotoxic lesions and preventing replication stress[1]. Dysfunction or mutations in SPRTN are implicated in Ruijs–Aalfs syndrome, a progeroid disorder characterized by genomic instability, premature aging, and a predisposition to cancers, especially hepatocellular carcinoma[1][3][5]. SPRTN also coordinates DNA damage tolerance pathways, influencing the switch between replicative and translesion synthesis DNA polymerases and broader aspects of DNA repair and genome maintenance[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA-dependent metalloprotease SPRTN (SPRTN).